Protocol Ledger

NCT05379634 · Phase II · COMPLETED

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

Interventional Phase II clinical trial protocol NCT05379634 sponsored by Johnson & Johnson / Janssen in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-07-05 Enrollment: 36 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05379634
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)36 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05379634
Protocol FieldVerified Registry Value
NCT IdentifierNCT05379634
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment36 participants (ACTUAL)
Registered Start Date2022-07-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI